{"indexed":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T06:41:17Z","timestamp":1559112077737},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"URL":"http:\/\/www.springer.com\/tdm","start":{"date-parts":[[2008,11,1]],"date-time":"2008-11-01T00:00:00Z","timestamp":1225497600000},"delay-in-days":0,"content-version":"tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"published-print":{"date-parts":[[2008,11]]},"DOI":"10.1007\/s00774-008-0852-6","type":"article-journal","created":{"date-parts":[[2008,10,31]],"date-time":"2008-10-31T10:41:20Z","timestamp":1225449680000},"page":"635-641","source":"Crossref","is-referenced-by-count":16,"title":"Scintigraphic, biochemical, and clinical response to zoledronic acid treatment in patients with Paget\u2019s disease of bone","prefix":"10.1007","volume":"26","author":[{"given":"Avraam","family":"Avramidis","sequence":"first","affiliation":[]},{"given":"Stergios A.","family":"Polyzos","sequence":"additional","affiliation":[]},{"given":"Efstratios","family":"Moralidis","sequence":"additional","affiliation":[]},{"given":"Georgios","family":"Arsos","sequence":"additional","affiliation":[]},{"given":"Zoe","family":"Efstathiadou","sequence":"additional","affiliation":[]},{"given":"Konstantinos","family":"Karakatsanis","sequence":"additional","affiliation":[]},{"given":"Georgios","family":"Grollios","sequence":"additional","affiliation":[]},{"given":"Marina","family":"Kita","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2008,11,1]]},"reference":[{"key":"852_CR1","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/S8756-3282(02)00817-7","volume":"31","author":"P.L. Selby","year":"2002","unstructured":"Selby PL, Davie MW, Ralston SH, Stone MD (2002) Guidelines on the management of Paget\u2019s disease of bone. Bone (NY) 31:366\u2013373","journal-title":"Bone (NY)"},{"key":"852_CR2","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s00774-006-0696-x","volume":"24","author":"S. Takata","year":"2006","unstructured":"Takata S, Hashimoto J, Nakatsuka K, Yoshimura N, Yoh K, Ohno I, Yabe H, Abe S, Fukunaga M, Terada M, Zamma M, Ralston SH, Morii H, Yoshikawa H (2006) Guidelines for diagnosis and management of Paget\u2019s disease of bone in Japan. J Bone Miner Metab 24:359\u2013367","journal-title":"J Bone Miner Metab"},{"issue":"suppl2","key":"852_CR3","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1359\/jbmr.06s201","volume":"21","author":"C. Cooper","year":"2006","unstructured":"Cooper C, Harvey NC, Dennison EM, van Staa TP (2006) Update on the epidemiology of Paget\u2019s disease of bone. J Bone Miner Res 21(suppl 2):3\u20138","journal-title":"J Bone Miner Res"},{"issue":"suppl2","key":"852_CR4","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1359\/jbmr.06s203","volume":"21","author":"L. Gennari","year":"2006","unstructured":"Gennari L, Merlotti D, Martini G, Nuti R (2006) Paget\u2019s disease of bone in Italy. J Bone Miner Res 21(suppl 2):14\u201321","journal-title":"J Bone Miner Res"},{"issue":"suppl2","key":"852_CR5","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1359\/jbmr.06s217","volume":"21","author":"P.L. Selby","year":"2006","unstructured":"Selby PL (2006) Guidelines for the diagnosis and management of Paget\u2019s disease: a UK perspective. J Bone Miner Res 21(suppl 2):92\u201393","journal-title":"J Bone Miner Res"},{"key":"852_CR6","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1359\/jbmr.061001","volume":"22","author":"D. Hosking","year":"2007","unstructured":"Hosking D, Lyles K, Brown JP, Fraser WD, Miller P, Curiel MD, Devogelaer JP, Hooper M, Su G, Zelenakas K, Pak J, Fashola T, Saidi Y, Eriksen EF, Reid IR (2007) Long-term control of bone turnover in Paget\u2019s disease with zoledronic acid and risedronate. J Bone Miner Res 22:142\u2013148","journal-title":"J Bone Miner Res"},{"key":"852_CR7","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1056\/NEJMoa044241","volume":"353","author":"I.R. Reid","year":"2005","unstructured":"Reid IR, Miller P, Lyles K, Fraser W, Brown JP, Saidi Y, Mesenbrink P, Su G, Pak J, Zelenakas K, Luchi M, Richardson P, Hosking D (2005) Comparison of a single infusion of zoledronic acid with risedronate for Paget\u2019s disease. N Engl J Med 353: 898\u2013908","journal-title":"N Engl J Med"},{"issue":"suppl2","key":"852_CR8","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1359\/jbmr.06s215","volume":"21","author":"I.R. Reid","year":"2006","unstructured":"Reid IR (2006) Zoledronate: efficacy and safety. J Bone Miner Res 21(suppl 2):83\u201387","journal-title":"J Bone Miner Res"},{"issue":"suppl2","key":"852_CR9","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1359\/jbmr.06s218","volume":"21","author":"E.S. Siris","year":"2006","unstructured":"Siris ES, Lyles KW, Singer FR, Meunier PJ (2006) Medical management of Paget\u2019s disease of bone: indications for treatment and review of current therapies. J Bone Miner Res 21(suppl 2):94\u201398","journal-title":"J Bone Miner Res"},{"key":"852_CR10","doi-asserted-by":"crossref","first-page":"793","DOI":"10.2165\/00003495-200767050-00011","volume":"67","author":"G.M. Keating","year":"2007","unstructured":"Keating GM, Scott LJ (2007) Zoledronic acid: a review of its use in the treatment of Paget\u2019s disease of bone. Drugs 67:793\u2013804","journal-title":"Drugs"},{"key":"852_CR11","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.bone.2005.05.003","volume":"38","author":"G.H. Nancollas","year":"2006","unstructured":"Nancollas GH, Tang R, Phipps RJ, Henneman Z, Gulde S, Wu W, Mangood A, Russell RG, Ebetino FH (2006) Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone (NY) 38:617\u2013627","journal-title":"Bone (NY)"},{"key":"852_CR12","first-page":"235","volume":"296","author":"J.E. Dunford","year":"2001","unstructured":"Dunford JE, Thompson K, Coxon FP, Luckman SP, Hahn FM, Poulter CD, Ebetino FH, Rogers MJ (2001) Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther 296:235\u2013242","journal-title":"J Pharmacol Exp Ther"},{"key":"852_CR13","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1007\/s00223-007-9012-6","volume":"80","author":"J. Shapiro","year":"2007","unstructured":"Shapiro J, Smith B, Beck T, Ballard P, Dapthary M, BrintzenhofeSzoc K, Caminis J (2007) Treatment with zoledronic acid ameliorates negative geometric changes in the proximal femur following acute spinal cord injury. Calcif Tissue Int 80:316\u2013322","journal-title":"Calcif Tissue Int"},{"key":"852_CR14","first-page":"464","volume":"25","author":"K. Tziomalos","year":"2007","unstructured":"Tziomalos K, Florentin M, Krikis N, Perifanis V, Karagiannis A, Harsoulis F (2007) Persistent effect of zoledronic acid in Paget\u2019s disease. Clin Exp Rheumatol 25:464\u2013466","journal-title":"Clin Exp Rheumatol"},{"key":"852_CR15","first-page":"1359","volume":"42","author":"J.A. Carrasquillo","year":"2001","unstructured":"Carrasquillo JA, Whatley M, Dyer V, Figg WD, Dahut W (2001) Alendronate does not interfere with 99mTc-methylene diphosphonate bone scanning. J Nucl Med 42:1359\u20131363","journal-title":"J Nucl Med"},{"key":"852_CR16","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1097\/00006231-199011000-00004","volume":"11","author":"U. Patel","year":"1990","unstructured":"Patel U, Gallacher SJ, Boyle IT, McKillop JH (1990) Serial bone scans in Paget\u2019s disease: development of new lesions, natural variation in lesion intensity and nature of changes seen after treatment. Nucl Med Commun 11:747\u2013760","journal-title":"Nucl Med Commun"},{"key":"852_CR17","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1259\/0007-1285-58-696-1165","volume":"58","author":"C.J. Vellenga","year":"1985","unstructured":"Vellenga CJ, Pauwels EK, Bijvoet OL, Harinck HI, Frijlink WB (1985) Quantitative bone scintigraphy in Paget\u2019s disease treated with APD. Br J Radiol 58:1165\u20131172","journal-title":"Br J Radiol"},{"key":"852_CR18","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1097\/00006231-199906000-00006","volume":"20","author":"F. Pons","year":"1999","unstructured":"Pons F, Alvarez L, Peris P, Guanabens N, Vidal-Sicart S, Monegal A, Pavia J, Ballesta AM, Munos-Gomez J, Herranz R (1999) Quantitative evaluation of bone scintigraphy in the assessment of Paget\u2019s disease activity. Nucl Med Commun 20:525\u2013528","journal-title":"Nucl Med Commun"},{"key":"852_CR19","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1259\/0007-1285-50-592-243","volume":"50","author":"J.P. Lavender","year":"1977","unstructured":"Lavender JP, Evans IM, Arnot R, Bowring S, Doyle FH, Joplin GF, MacIntyre I (1977) A comparison of radiography and radioisotope scanning in the detection of Paget\u2019s disease and in the assessment of response to human calcitonin. Br J Radiol 50: 243\u2013250","journal-title":"Br J Radiol"},{"key":"852_CR20","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1148\/125.3.761","volume":"125","author":"A.D. Waxman","year":"1977","unstructured":"Waxman AD, Ducker S, McKee D, Siemsen JK, Singer FR (1977) Evaluation of 99mTc diphosphonate kinetics and bone scans in patients with Paget\u2019s disease before and after calcitonin treatment. Radiology 125:761\u2013764","journal-title":"Radiology"},{"key":"852_CR21","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0009-9260(76)80037-2","volume":"27","author":"B.C. Lentle","year":"1976","unstructured":"Lentle BC, Russell AS, Heslip PG, Percy JS (1976) The scintigraphic findings in Paget\u2019s disease of bone. Clin Radiol 27: 129\u2013135","journal-title":"Clin Radiol"},{"key":"852_CR22","first-page":"94","volume":"127","author":"M. Rashid","year":"1977","unstructured":"Rashid M, Khairi A, Johnston C Jr (1977) Treatment of Paget\u2019s disease of bone (osteitis deformans) with sodium etidronate (EHDP). Clin Orthop Relat Res 127:94\u2013105","journal-title":"Clin Orthop Relat Res"},{"key":"852_CR23","doi-asserted-by":"crossref","first-page":"280","DOI":"10.4158\/EP.9.4.280","volume":"9","author":"G. Ang","year":"2003","unstructured":"Ang G, Feiglin D, Moses AM (2003) Symptomatic and scintigraphic improvement after intravenous pamidronate treatment of Paget\u2019s disease of bone in patients with normal serum alkaline phosphatase levels. Endocr Pract 9:280\u2013283","journal-title":"Endocr Pract"},{"key":"852_CR24","first-page":"1589","volume":"33","author":"P.J. Ryan","year":"1992","unstructured":"Ryan PJ, Gibson T, Fogelman I (1992) Bone scintigraphy following intravenous pamidronate for Paget\u2019s disease of bone. J Nucl Med 33:1589\u20131593","journal-title":"J Nucl Med"},{"key":"852_CR25","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.bone.2004.03.023","volume":"35","author":"I.R. Reid","year":"2004","unstructured":"Reid IR, Davidson JS, Wattie D, Wu F, Lucas J, Gamble GD, Rutland MD, Cundy T (2004) Comparative responses of bone turnover markers to bisphosphonate therapy in Paget\u2019s disease of bone. Bone (NY) 35:224\u2013230","journal-title":"Bone (NY)"},{"key":"852_CR26","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/0221-8747(81)90040-0","volume":"3","author":"I. Fogelman","year":"1981","unstructured":"Fogelman I, Carr D, Boyle IT (1981) The role of bone scanning in Paget\u2019s disease. Metab Bone Dis Relat Res 3:243\u2013254","journal-title":"Metab Bone Dis Relat Res"},{"key":"852_CR27","first-page":"154","volume":"3","author":"C.J. Vellenga","year":"1988","unstructured":"Vellenga CJ, Bijvoet OL, Pauwels EK (1988) Bone scintigraphy and radiology in Paget\u2019s disease of bone: a review. Am J Physiol Imaging 3:154\u2013168","journal-title":"Am J Physiol Imaging"},{"key":"852_CR28","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1210\/jcem-42-3-459","volume":"42","author":"A. Avramides","year":"1976","unstructured":"Avramides A, Flores A, DeRose J, Wallach S (1976) Paget\u2019s disease of the bone: observations after cessation of long-term synthetic salmon calcitonin treatment. J Clin Endocrinol Metab 42:459\u2013463","journal-title":"J Clin Endocrinol Metab"},{"issue":"suppl2","key":"852_CR29","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1359\/jbmr.06s216","volume":"21","author":"S.E. Papapoulos","year":"2006","unstructured":"Papapoulos SE, Eekhoff EM, Zwinderman AH (2006) Acquired resistance to bisphosphonates in Paget\u2019s disease of bone. J Bone Miner Res 21(suppl 2):88\u201391","journal-title":"J Bone Miner Res"},{"key":"852_CR30","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1359\/jbmr.070704","volume":"22","author":"D. Merlotti","year":"2007","unstructured":"Merlotti D, Gennari L, Martini G, Valleggi F, De PV, Avanzati A, Nuti R (2007) Comparison of different intravenous bisphosphonate regimens for Paget\u2019s disease of bone. J Bone Miner Res 22:1510\u20131517","journal-title":"J Bone Miner Res"},{"key":"852_CR31","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1359\/jbmr.2003.18.5.868","volume":"18","author":"S.C. Cremers","year":"2003","unstructured":"Cremers SC, Eekhoff ME, Den HJ, Hamdy NA, Vermeij P, Papapoulos SE (2003) Relationships between pharmacokinetics and rate of bone turnover after intravenous bisphosphonate (olpadronate) in patients with Paget\u2019s disease of bone. J Bone Miner Res 18:868\u2013875","journal-title":"J Bone Miner Res"},{"key":"852_CR32","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/jbmr.5650070308","volume":"7","author":"M.D. Stone","year":"1992","unstructured":"Stone MD, Marshall DH, Hosking DJ, Perkins AC, Evans AJ, Wastie ML (1992) Bisphosphonate space measurement in Paget\u2019s disease of bone treated with APD. J Bone Miner Res 7:295\u2013301","journal-title":"J Bone Miner Res"},{"key":"852_CR33","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1210\/edrv.19.1.0325","volume":"19","author":"H. Fleisch","year":"1998","unstructured":"Fleisch H (1998) Bisphosphonates: mechanisms of action. Endocr Rev 19:80\u2013100","journal-title":"Endocr Rev"},{"key":"852_CR34","doi-asserted-by":"crossref","first-page":"7829","DOI":"10.1073\/pnas.0601643103","volume":"103","author":"K.L. Kavanagh","year":"2006","unstructured":"Kavanagh KL, Guo K, Dunford JE, Wu X, Knapp S, Ebetino FH, Rogers MJ, Russell RG, Oppermann U (2006) The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs. Proc Natl Acad Sci U S A 103:7829\u20137834","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":"Journal of Bone and Mineral Metabolism","original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00774-008-0852-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00774-008-0852-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00774-008-0852-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T06:14:22Z","timestamp":1559110462000},"score":1.0,"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,11]]},"references-count":34,"journal-issue":{"published-print":{"date-parts":[[2008,11]]},"issue":"6"},"alternative-id":["852"],"URL":"http:\/\/dx.doi.org\/10.1007\/s00774-008-0852-6","relation":{"cites":[]},"ISSN":["0914-8779","1435-5604"],"subject":["Endocrinology, Diabetes and Metabolism","Endocrinology","Orthopedics and Sports Medicine","General Medicine"],"container-title-short":"J Bone Miner Metab"}